DoD Kideny Cancer, Technology Development Award

Description

The KCRP Technology Development Award is aproduct-driven award mechanism intended to advance the development oftechnologies to aid kidney cancer clinical and patient outcomes, includingprevention, detection, diagnosis, treatment, or quality of life. Applicantswith limited kidney cancer experience are strongly encouraged to collaboratewith those having substantial expertise in kidney cancer research and/or kidneycancer model systems. Applications must describe how the technologywill enhance the existing knowledge of kidney cancer. The product(s)to be developed may be a tangible item such as a pharmacologic agent (drugs orbiologics) or device. The Principal Investigator (PI) must provide a transitionplan (including potential funding and resources) showing how the product willprogress to the next level of development (e.g., clinical trials, delivery tothe military or civilian market) after the completion of the KCRP award. Applications must include preliminary datarelevant to the proposed phase of development (data does not have to be inkidney cancer). Informative clinical data from a related human disease may beused to support the rationale for the proposed study. These data may beunpublished and/or from the published literature. Investigators seeking toidentify a product should consider submitting to the FY18 KCRP Concept Award(W81XWH-18-KCRP-CA) or the FY18 KCRP Idea Development Award(W81XWH-18-KCRP-IDA), as appropriate. Examples of the types ofresearch that may be supported include, but are not limited to: Use ofartificial intelligence to identify novel targets for kidney cancer therapyand/or biomarkers of response/resistance to therapeutics. Platformdevelopment or adaptation to provide ultrasensitive, multiplexed detection ofgenomic, proteomic, and metabolic biomarkers to determine renal cell carcinoma(RCC) molecular phenotype and/or disease status from a single biological sample(e.g., tissue, blood, urine). Technologyapplication to enable dissemination of accurate and up-to-date kidney cancerinformation to patients and caregivers. Developmentof a virtual annotated tumor bank that may be used by the research community asa resource to study molecular characteristics, disease status, populationdemographics, etc. Licensing andCommercialization Partners: Applicants are encouraged to identify and foster relationshipswith potential licensing and commercialization partners early in thedevelopment process. Biotechnology or pharmaceutical companies intending toapply for the Therapeutic Development Award are encouraged to leverage theirown resources to complement the funding provided by this award. Participatingorganizations should ensure the success of the collaboration by resolvingpotential intellectual and material property issues and by removingorganizational barriers that might interfere with achieving high levels ofcooperation. Letters confirming/supporting the collaboration are required. Theanticipated direct costs budgeted for the entire period of performance for anFY18 KCRP Technology Development Award will not exceed $300,000. Referto SectionII.D.5, Funding Restrictions, for detailed funding information. The proposed research mustbe relevant to active duty Service members, Veterans, military beneficiaries,and/or the American public.

Agency Contact

More from Defense Health Agency Contracting Activity - DHACA